choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Herceptin & Breast Cancer

Herceptin & Breast Cancer Newsletter
  • FDA approves Hercessi as latest interchangeable Herceptin biosimilar 01 May 2024 17:15 GMT

    … HER2-overexpressing breast cancer, treatment of HER2-overexpressing metastatic breast cancer and treatment … trastuzumab-strf and trastuzumab (Herceptin, Genentech) to be highly … with HER2-overexpressing metastatic breast cancer in combination with docetaxel. …

  • U.S. Food & Drug Administration approves Accord BioPharma’s HERCESSI, a biosimilar to Herceptin 01 May 2024 17:11 GMT

    … strf), a biosimilar to Herceptin (trastuzumab), to treat … breast cancer, the treatment of HER2-overexpressing metastatic breast cancer, … HER2-overexpressing metastatic breast cancer in combination with … between HERCESSI and Herceptin in the populations …

  • Herceptin Biosimilar, Hercessi, Approved by FDA in Breast, Gastric Cancers 29 Apr 2024 21:47 GMT

    … to Herceptin (trastuzumab) for the adjuvant (postsurgical) treatment of HER2-overexpressing breast cancer … , HER2-overexpressing metastatic breast cancer and HER2-overexpressing metastatic …

  • Younger Patients With HER2+ Breast Cancer May Benefit from Surgery First 17 Apr 2024 22:06 GMT

    … with HER2-positive breast cancer may experience better … positive, invasive, nonmetastatic breast cancer who received neoadjuvant … with HER2-positive breast cancer. CancerNetwork: Could … their therapy from trastuzumab [Herceptin] and pertuzumab [Perjeta …

  • Boryung and Bixink to co-market Nerlynx for HER2-positive breast cancer 04 Apr 2024 04:50 GMT

    … promotion agreement with Boryung for breast cancer treatment. Accordingly, starting … ExteNET. While existing drugs, including Herceptin (trastuzumab), Perjeta (pertuzumab) combination … rate of HER2-positive breast cancer patients through clinical studies, …

  • Novel Injection Earns FDA ODD in Breast Cancer Brain Metastases 03 Apr 2024 20:45 GMT

    … those with triple-negative breast cancer brain metastases. Previously, … treatment, previously treated breast cancer brain metastases that … a response from trastuzumab (Herceptin) or pyrotinib. The … bevacizumab for advanced breast cancer with brain metastases. …

  • Expert Overview of HER2-Positive Breast Cancer Treatment 01 Apr 2024 21:19 GMT

    … Actionable Biomarker’ in Breast Cancer Subset Tripathy is a … At the Miami Breast Cancer Conference, he sat … breast cancer treatment. He discussed how clinicians use HER2-targeting antibodies like Herceptin … given with [Herceptin]. Then the [Herceptin] continues …

  • Metastatic Breast Cancer Treatments and Breakthroughs of 2021 01 Apr 2024 00:21 GMT

    … advanced, or metastatic breast cancer. Alpelisib is a … approved biosimilars to Herceptin for breast cancer: Ontruzant (trastuzumab- … metastasized HER2-negative breast cancer. Histone deacetylase ( … hormone receptor-positive breast cancer. Tucidinostat has shown …

  • Amplifying Immune Responses: Microparticulate Vaccine Approach Against Breast Cancer 28 Mar 2024 13:57 GMT

    breast cancer, with 43,170 deaths attributed to breast cancer.1 Even more devastating, breast cancer … immunotherapies for breast cancer, including pembrolizumab … with trastuzumab (Herceptin). A detailed … model of breast cancer. Breast Cancer Res Treat. …

  • Phesgo for the Treatment of HER2-Positive Breast Cancer, US 19 Mar 2024 05:52 GMT

    … -positive breast cancer causes and symptoms Breast cancer remains one … -positive breast cancer can be either early breast cancer, which … Herceptin, the standard therapy for HER2-positive breast cancer, … for HER2-positive breast cancer favoured SC administration …

Satisfied with the content?

Continue to create your account.